Of the 48 eligible patients, 26 received hyaluronidase and 22 received placebo. The mean CK serum entry was 3140 ± 2111 mIU/ml (mean ± SD) in hyaluronidase patients and 3574 ± 1476 mIU/ml in placebo patients (p < 0.21). The mean infarct size was 54.6 ± 35.8 CK gram-equivalents in the hyaluronidase patients and 64.0 ± 31.1 CK gram-equivalents in the placebo patients (p < 0.20). Among the 21 patients treated within 6 hours of the onset of infarction, the difference in infarct size was greater (p < 0.15). There was no significant difference in the incidence of power failure, ventricular arrhythmias, recurrence of ischemic pain, infarct extension or mortality. No benefit of hyaluronidase was demonstrated in this study, which was designed to detect a 50% reduction of infarct size. However, to detect a 20% reduction in infarct size would require a much larger study population.
SUMMARY Patients with their first myocardial infarction not initially complicated by severe atrioventricular block or power failure were given a skin test and then randomized to receive either hyaluronidase or placebo in double-blind fashion. Hyaluronidase, 500 IU/kg i.v., was given every 6 hours for 42 hours.
Of the 48 eligible patients, 26 received hyaluronidase and 22 received placebo. The mean CK serum entry was 3140 ± 2111 mIU/ml (mean ± SD) in hyaluronidase patients and 3574 ± 1476 mIU/ml in placebo patients (p < 0.21). The mean infarct size was 54.6 ± 35.8 CK gram-equivalents in the hyaluronidase patients and 64.0 ± 31.1 CK gram-equivalents in the placebo patients (p < 0.20). Among the 21 patients treated within 6 hours of the onset of infarction, the difference in infarct size was greater (p < 0.15). There was no significant difference in the incidence of power failure, ventricular arrhythmias, recurrence of ischemic pain, infarct extension or mortality. No benefit of hyaluronidase was demonstrated in this study, which was designed to detect a 50% reduction of infarct size. However, to detect a 20% reduction in infarct size would require a much larger study population.
THE CONCEPT that the extent of myocardial necrosis developing during the course of a myocardial infarction can be influenced by many factors independent of the underlying coronary pathology and collateral blood supply has been the focus of extensive investigation.' The importance of infarct size is attested to by evidence of positive correlations between infarct size and the incidence of cardiogenic shock,2 frequency of ventricular arrhythmias,3 the severity of hemodynamic abnormalities,4 and prognosis in the hospital5 and after discharge.6 It is presumed that a zone of ischemic tissue surrounds an area of necrosis, and that the fate of this border zone depends on various influences on the infarcted ventricle,8-'0 but this concept is controversial."
Attempts to limit human infarct size are based on evidence from animal studies that certain interventions may limit the extent of myocardial necrosis after experimental coronary artery occlusion. Although many interventions appear to limit infarct size in animals, only a few have been documented in humans, among them propranolol,'2' 13 practolol,14 nitroglycerin, '1' 16 trimethaphan17 and hyaluronidase. 18 Quantitation of infarct size in the living patient is difficult. The two principal techniques are ECG mapping19 and the serial CK technique.20' 21 Both have been refined extensively since their introduction, but many problems persist and significant disparities between estimated and pathologic infarct size can occur in individual subjects.
Hyaluronidase is an enzyme that depolymerizes the mucopolysaccharide hyaluronic acid of the intracellular ground substance. 22 Hg , absence of pulmonary edema (wet rales at least one-third of the way up the posterior chest and interstitial edema on the x-ray). Eligible patients were asked for informed consent.
Intramuscular injections were prohibited for the remainder of the study and cardioversion was cause for rejection. A heparin lock was placed in a large freeflowing vein and serial 2-ml blood samples were obtained at 2-hour intervals for 72-96 hours. The samples were stored at 4°C and centrifuged; the serum was stored at -20°C. CK analysis was carried out in duplicate as a batch for each patient, using the SKI bulk reagent modification of the Rosalki method34 at 37°C in a single research laboratory.
Hyaluronidase of bovine testicular origin (Wyeth Ltd.) was obtained in a concentration of 7500 IU/vial and diluted with 2 ml of distilled water at the time of administration. Every eligible patient had a scratch test in which one drop of saline and one drop of hyaluronidase were applied to adjacent scratches on the forearm. If wheal and flare were absent after 5 minutes, 0.01 ml of saline and 0.01 ml of hyaluronidase were injected intradermally at adjacent sites. Absence of a wheal and flare after 10 minutes determined final eligibility for the study.
Lyophilized hyaluronidase and lactose placebo were prepared in identical vials and stored in boxes of 40 vials each. The boxes were block-randomized in groups of four using a random number sequence, and the boxes were then numbered consecutively. The identifying code was filed in the hospital pharmacy and in the Department of Epidemiology and Biostatistics, but was not available to the investigators or clinical personnel except in the event of an emergency. The code was not broken until all data were analyzed. Each patient was assigned a number from 1-60 and received the corresponding medication. The initial dose of hyaluronidase was 500 IU/kg lean body weight, administered as an i.v. bolus over 1-2 minutes. The dose was repeated seven times at 6-hour intervals.
Infarct Size
Infarct size was measured by the serial CK technique21 as modified by Norris et al. 35 Each measured CK value was corrected by subtraction of 100 mIU/ml (mean normal) and was plotted on a log scale y-axis. Time was on the x-axis with 0 time as the onset of the characteristic pain of myocardial 'infarction. The curve was visually inspected for the point where the steep linear downslope began. The first point selected on this portion of the curve was always at least the third successive decreasing value in relation to the preceding two values. Subsequent points were included only down to a measured value of 250 mIU/ml (elevation of 150 mIU/ml) to minimize the deviations from the exponential regression model that often became apparent at these low levels. An exception was made'for very small myocardial infarctions (peak CK value less than 600 mIU/ml) where these low CK values were significant proportions of the total downslope points available for analysis. The points were fitted to an exponential regression to yield Kd (exponential CK disappearance rate) and r2 (correlation coefficient) for each patient. If Patients were interviewed twice daily for the recurrence of chest pain by nursing and study personnel. A recurrence of ischemic pain after the first 24 hours of hospitalization was considered to have occurred if the patient experienced pain in the chest or characteristic referral areas, similar in character to that precipitating admission, and lasting at least 10 minutes. The pain of pericarditis was specifically looked for and ruled out.
Myocardial infarction extension was defined as recurrence of ischemic pain in the chest or characteristic referral areas, accompanied by a further increase of CK to at least 200 mIU/ml.
Statistical Methods
Separate comparisons of CKr, peak serum CK, and CK infarct size were made between the 26 hyaluronidase-treated patients and the 22 control patients using unpaired t tests. CKr of the 12 hyaluronidase-treated patients and the nine control patients who began therapy less than 6 hours after the onset of infarction was also evaluated using an unpaired t test.
Results
Between July 1977 and April 1979, 55 patients were judged to have met the entry criteria and underwent skin testing. Three patients had a wheal and flare reaction at least 5 mm in diameter and were excluded. Fifty-two patients began i.v. therapy, but two of them had no ST-segment elevation and therapy was discontinued before all doses were given; no increase in CK or change in ECG occurred. One patients received all doses of medication, but was then found to have entered the trial 19.5 hours after the onset of pain. Therefore, 49 patients were appropriate entrants to the trial; however, one died within 7 hours after initiation of therapy. The autopsy revealed external cardiac rupture through an acute anterior wall infarction. Infarct size could not be calculated because only three CK samples had been obtained by the time of death. The three ineligible patients and the patient who died were excluded from analysis without knowledge of whether they had received hyaluronidase or placebo. Therefore, 48 patients constitute the study group. Table 1 is a summary of clinical data.
The mean CKr was 3140 ± 2111 mIU/ml (± SD) in the hyaluronidase-treated patients, and 3574 ± 1476 mIU/ml in the control patients (p < 0.21) (fig. 1) Among the 21 patients who began therapy less than 6 hours after the onset of myocardial infarction, the mean CKr was 3151 ± 2181 mIU/ml in the hyaluronidase-treated group and 4055 ± 1509 mIU/ml in the placebo group (p < 0.15).
There was no significant difference in the incidence of moderate-to-severe power failure, moderate-tosevere ventricular arrhythmias and conduction disorders, the incidence of ischemic pain recurrence or the incidence of infarct extension between the hyaluronidase-treated and the placebo groups (table 1) .
The patient ruled nonanalyzable because of early death from anterior myocardial rupture had been receiving placebo. Patient 14 in the hyaluronidase group died suddenly on day 13 with ventricular fibrillation; permission for autopsy was refused. The mean follow-up in the hyaluronidase patients was 12 months (range 3-26 months), with one additional death at 10 months. The mean follow-up in the placebo patients was 13 months (range 6-25 months), with one death at 2.5 months. None of the 26 hyaluronidase-treated patients had an allergic reaction during their hospital stay. Sixteen of these patients had skin tests 3-6 months after treatment and none had a positive reaction.
Discussion
Administration of hyaluronidase at a mean of 6.9 hours after the onset of acute infarction did not result in reduction of infarct size compared with placebotreated patients. The likelihood that a true difference as great as 50% in infarct size would have been missed is 0.006. The less sensitive clinical variables (moderate-to-severe power failure, moderate-to-severe ventricular arrhythmia, ischemic pain, myocardial infarct extension, death) did not differ significantly between the hyaluronidase-treated and placebo groups. The outcomes in this study require further examination in relation to the data from other studies of the limitation of myocardial infarct size by hyaluronidase.
Bovine testicular hyaluronidase (molecular weight 60,000) catalyzes the degradation of hyaluronic acid, an important constituent of the intracellular ground substance.22' 23 Evidence of increased intracellular diffusional transport prompted the studies of de FIGURE 1. Mean cumulative entry of CK into 1 ml of serum (CKr) (left) peak serum CK (middle) and CK infarct size (right) in the 22 placebo and 26 hyaluronidase-treated patients. The vertical lines indicate standard deviation. 22 26 Oliviera et al., 24 32 8  53  10  58  11  48  15  68  18  46  20  52  22  53  24  48  25  47  28  54  30  37  31 64 ping, only patients with transmural anterior of anterolateral infarction entered the study. The difference in ECG evolution between the hyaluronidase-treated and the control patients cannot be quantitatively related to the extent of myocardial necrosis.
All patients entered the study of Maroko et al.19 within 8 hours (mean 4.6 hours) after the onset of acute myocardial infarction. In the present study, the mean time from the onset of myocardial infarction to hyaluronidase therapy was 6.9 hours, similar to that in several other studies of infarct size, but the upper limit of 12 hours may have been excessive. Peter et al.13 demonstrated decreased infarct size in propranolol patients only when therapy was started within 4 hours after the onset of myocardial infarction. The likely importance of early therapy is suggested by the more marked difference ofCK release and the approach to statistical significance for the difference between hyaluronidase-treated and control patients entering the present study within 6 hours after pain began.
The serial CK method of estimating infarct size is problematic. The constants that relate serum appearance of CK to myocardial release were developed in dogs, and most have been assumed to be similar in humans. However, rather wide standard deviations exist for the constants in dogs;-6 the ratio of CK serum entry to myocardial CK loss varies inversely with infarct size;37 there may be ongoing CK release beyond the plateau of the cumulative release curve;38 and there is evidence of biexponential disappearance and twocompartment distribution of CK.39 The divergences from the original theoretical model may reduce the likelihood of sensitive comparisons of infarct size, and may have obscured a real, though modest, difference in infarct size between hyaluronidase-treated and control patients in the present study.
The possibility that a given intervention might systematically alter certain of the constants relating the peripheral appearance of CK to the myocardial loss must also be considered. Because hyaluronidase increases intracellular diffusional transport, the rate of CK serum entry to myocardial CK loss might be higher in patients receiving hyaluronidase, which would result in spuriously large calculated infarct sizes. If this were so, one would predict that peak and plateau CK levels in the serum would be achieved more quickly in hyaluronidase-treated than in control patients. In the present series, there was no significant difference between hyaluronidase-and placebo-treated patients in mean time to peak CK (21. hemodynamic and clinical response. We studied 22 consecutive patients with chronic refractory pump failure (group A) and 18 patients with acute myocardial infarction and pump failure (group B) (table 1) . Refractory pump failure (group A) was manifest by persistent left-heart failure despite intensive conventional therapy. All patients in this category had dyspnea and hypoxia, wet rales and radiographic evidence of pulmonary venous congestion and cardiomegaly. Medical therapy in these patients included large i.v. doses of potent diuretics, digitalis, and bed rest in hospital. Other therapy included correction of electrolyte imbalance and treatment of arrhythmias.
The patients with chronic ischemic failure (group A, subgroup 1) all had recurrent myocardial infarction. These patients were not considered for surgery either because of their poor left ventricular function or because their coronary anatomy did not appear amenable to bypass grafting. Poor left ventricular function was demonstrated noninvasively or by complete cardiac catheterization and angiography. The left ventricular ejection fraction was less than 25% with diffuse hypokinesis and areas of akinesis or dyskinesis on nuclear ventriculography and, when measured, left ventricular end-diastolic pressure was greater than 20 mm Hg. Five of the coronary patients had significant mitral regurgitation and systolic regurgitant murmurs. Mitral regurgitation was diagnosed in three patients as 3+ on contrast ventriculography and was docu-
